Company intelligence / Profile preview
ORPHELIA Pharma
Paris, Ile de France, Franceorphelia-pharma.eu ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Commercial
01
Overview
ORPHELIA Pharma has one drug (Kigabeq®) approved in the European Union and available in several countries. Another product (Kizfizo®), an oral liquid formulation of temozolomide, is currently under EU marketing authorization review[1].
- Therapeutic areas
- OncologyRare DiseasesNeurologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Regional distribution agreements in the European Union and elsewhere, academic and industrial partnerships[1]
Beyond the preview
Go deeper on ORPHELIA Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORPHELIA Pharma.